檢索結果 - Isaac Boss
- Showing 1 - 4 results of 4
-
1
P799: SYNERGISTIC ANTITUMOR ACTIVITY OF THE BCMA 2 + 1 T CELL ENGAGER (TCE) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) AND CELMOD AGENTS IN MULTIPLE MYELOMA (MM) PRECLINICAL MODELS... 由 Bruno Paiva, Bonny Gaffney, Kelven Burnett, Paola Castiglioni, Michael Angelo, Daniel W. Pierce, Isaac Boss
發表在 HemaSphere (2023-08-01)獲取全文
Article -
2
P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MUL... 由 Isaac Boss, Ethan Thompson, Allison Gaudy, Thi Minh Diem Vu, Colin Godwin, Michael Burgess, Sandy W. Wong, Luciano Costa
發表在 HemaSphere (2023-08-01)獲取全文
Article -
3
Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine 由 Amer M. Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian A. Fox
發表在 Therapeutic Advances in Hematology (2024-06-01)獲取全文
Article -
4
Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab 由 Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac Boss, Lourdes Mendez, Nikolai Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian A. Fox, Amer M. Zeidan
發表在 Therapeutic Advances in Hematology (2025-06-01)獲取全文
Article